Juniper Biosciences LLC

Based in the US, Juniper Biosciences LLC offers innovative radiopharmaceuticals that enhance diagnostic and therapeutic solutions, targeting improved patient outcomes in healthcare. Juniper Biosciences LLC, founded in 2025, is located in Bridgewater, US, and focuses on the development of radiopharmaceuticals. In December 2025, Juniper Biosciences raised USD 40 million in seed funding co-led by new investors NovaCapital, Club Degli Investitori and individual investors. The founder's history is not specified, and there are no known subsidiaries or parent companies.

Juniper Biosciences specializes in the development of innovative radiopharmaceuticals aimed at transforming healthcare through enhanced diagnostic and therapeutic solutions. Their core product offerings leverage advanced radioisotopes linked to high-specificity ligands, enabling earlier disease diagnosis and more effective treatment with minimized side effects. These products are designed to address unmet medical needs primarily in oncology, focusing on improving patient outcomes in cancer and other diseases. The company targets healthcare providers, hospitals, and clinical laboratories within various geographical markets, including North America, Europe, and select regions in Asia, delivering solutions that improve both patient access and treatment efficacy.

Juniper Biosciences generates revenue through a structured transaction model that includes partnerships with healthcare institutions and sales to clinical entities. The company engages in direct-to-consumer and B2B transactions, supplying its innovative radiopharmaceutical agents to hospitals and diagnostic centers. Revenue is derived from the sale of its flagship products, designed to address critical therapeutic areas, with contracts typically structured around volume-based agreements or one-time purchases. These arrangements ensure a consistent flow of revenue as healthcare providers integrate Juniper's solutions into their treatment protocols, ultimately supporting enhanced patient care and facilitating earlier interventions in disease management.

In December 2025, Juniper Biosciences raised USD 40 mn in Seed funding, which will be utilized to advance preclinical studies and scale development of its RNA-based therapeutic pipeline. The company aims to introduce new products designed for oncology by targeting expansion into markets across Europe and Asia by 2026.